Respira Therapeutics Announces Agreement with Gossamer Bio for Potential Acquisition Respira Therapeutics has entered a pivotal agreement with Gossamer Bio to develop RT234, a groundbreaking therapy for pulmonary hypertension, enhancing patient relief options.

Respira Therapeutics Announces Agreement with Gossamer Bio for Potential Acquisition #United_States #Palo_Alto #Respira_Therapeutics #Gossamer_Bio #RT234